GSK In Pact With India’s Dr Reddy’s; Digs Deeper Into Emerging Generic Drugs Market
This article was originally published in PharmAsia News
Executive SummaryMUMBAI - Expanding its reach further into emerging markets for generic drugs, GlaxoSmithKline said it has reached an agreement with Dr. Reddy's Labs to develop and market select products across an extensive number of countries, except India
You may also be interested in...
The landmark 2009 deal between GSK and India’s Dr. Reddy’s to sell branded generic formulations in emerging markets is under serious review. While efforts are underway to redefine a future path and co-operate in a few areas, sources suggest a termination may be among the options being considered.
Dr. Reddy’s Chairman GV Prasad On Innovation, Biosimilars And Global Challenges: An Interview With PharmAsia News
GV Prasad, Chairman of the $2.13 billion Indian drug firm Dr. Reddy's Laboratories Ltd. is preparing to take his company from predominantly generics to super generics and untapped innovative niche products. His pet project is lower risk innovation via reverse translation by solving problems with existing molecules.
After a prolonged wait, Dr. Reddy’s finally finds rhythm in the worlds’ fastest growing market and eyes growth in niche areas.